Abstract:Optimal protein function often depends on co-operative interactions between amino acid residues distant in the protein primary sequence yet spatially near one another following protein folding. For example, antibody affinity is influenced by interactions of framework residues with complementarity-determining region (CDR) residues. However, despite the abundance of antibody structural information and computational tools the humanization of rodent antibodies for clinical use often results in a significant loss of affinity. To date, antibody engineering efforts have focused either on optimizing CDR residues involved in antigen binding or on optimizing antibody framework residues that serve critical roles in preserving the conformation of CDRs. In the present study a new approach which permits the rapid identification of co-operatively interacting framework and CDR residues was used to simultaneously humanize and optimize a murine antibody directed against CD40. Specifically, a combinatorial library that examined eight potentially important framework positions concomitantly with focused CDR libraries consisting of variants containing random single amino acid mutations in the third CDR of the heavy and light chains was expressed. Multiple anti-CD40 Fab variants containing as few as one murine framework residue and displaying up to approximately 500-fold higher affinity than the initial chimeric Fab were identified. The higher affinity humanized variants demonstrated a co-operative interaction between light chain framework residue Y49 and heavy chain CDR3 residue R/K101 (coupling energy, DeltaGI=0.9 kcal/mol). Screening of combinatorial framework-CDR libraries permits identification of monoclonal antibodies (mAb) with structures optimized for function, including instances in which the antigen induces conformational changes in the mAb. Moreover, the enhanced humanized variants contain fewer murine framework residues and could not be identified by sequential in vitro humanization and affinity muturation strategies. This approach to identifying co-operatively interacting residues is not restricted to antibody-antigen interactions and consequently, may be used broadly to gain insight into protein structure-function relationships, including proteins that serve as catalysts.

Affinity maturation of a human single-chain Fv by phage display

[Selection and Characterization of Human Antibodies Against Vascular Endothelial Growth Factor from Human Phage Display Antibody Library].

Affinity Maturation of Antiher2 Monoclonal Antibody Mil5 Using an Epitope-Specific Synthetic Phage Library by Computational Design

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

Advancement in the development of single chain antibodies using phage display technology

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity

Homology Modeling-Based in Silico Affinity Maturation Improves the Affinity of a Nanobody

The Improvement in Screening for Vascular Endothe Lial Growth Factor Receptor Flt-1 Antagonists in a Phage Display Library

Construction and Diversity Analysis of a Na(i)ve Human Phage-Displayed Fab Library

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

A review of in vitro stochastic and non-stochastic affinity maturation strategies for phage display derived monoclonal antibodies

Modification of phage display technique for improved screening of high-affinity binding peptides

Development of novel humanized VHH synthetic libraries based on physicochemical analyses

[Improving the Affinity of an Anti-Tnf-alpha Scfv by Random Mutation].

Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody

A compact phage display human scFv library for selection of antibodies to a wide variety of antigens

Mammalian cell display for the discovery and optimization of antibody therapeutics

Structure-guided Affinity Maturation of a Novel Human Antibody Targeting the SARS-CoV-2 Nucleocapsid Protein

Development and experimental validation of computational methods for human antibody affinity enhancement

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.